Submissions from 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial., Kaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, Parminder K Judge, Doreen Zhu, Emily Sammons, David Zi Cherney, Alfred K Cheung, Aldo P Maggioni, Masaomi Nangaku, Xavier Rossello, Katherine Tuttle, Katsuhito Ihara, Tomoko Iwata, Christoph Wanner, Jonathan Emberson, David Preiss, Martin J Landray, Colin Baigent FMedSci, Richard Haynes, and William G Herrington
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD., Kaitlin J Mayne, Natalie Staplin, David F Keane, Christoph Wanner, Susanne Brenner, Vladimir Cejka, Johannes Stegbauer, Parminder K Judge, David Preiss, Jonathan Emberson, Daniele Trinca, Rejive Dayanandan, Ryonfa Lee, John Nolan, Akiko Omata, Jennifer B Green, David Z I Cherney, Lai Seong Hooi, Roberto Pontremoli, Katherine Tuttle, Jennifer S Lees, Patrick B Mark, Simon J Davies, Sibylle J Hauske, Dominik Steubl, Martina Brückmann, Martin J Landray, Colin Baigent, Richard Haynes, William G Herrington, and EMPA-KIDNEY Collaborative Group
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD., Kaitlin J Mayne, Natalie Staplin, David F Keane, Christoph Wanner, Susanne Brenner, Vladimir Cejka, Johannes Stegbauer, Parminder K Judge, David Preiss, Jonathan Emberson, Daniele Trinca, Rejive Dayanandan, Ryonfa Lee, John Nolan, Akiko Omata, Jennifer B Green, David Z I Cherney, Lai Seong Hooi, Roberto Pontremoli, Katherine Tuttle, Jennifer S Lees, Patrick B Mark, Simon J Davies, Sibylle J Hauske, Dominik Steubl, Martina Brückmann, Martin J Landray, Colin Baigent, Richard Haynes, William G Herrington, and EMPA-KIDNEY Collaborative Group
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk., Rozalina G McCoy, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, David M Kent, Joseph S Ross, Guillermo E Umpierrez, Rodolfo J Galindo, William H Crown, Bijan J Borah, Victor M Montori, Juan P Brito, Joshua J Neumiller, Mindy M Mickelson, and Eric C Polley
Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study., Yuichiro Mori, Toshiaki Komura, Motohiko Adomi, Ryuichiro Yagi, Shingo Fukuma, Naoki Kondo, Motoko Yanagita, O Kenrik Duru, Katherine Tuttle, and Kosuke Inoue
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD., Sankar D Navaneethan, Nisha Bansal, Kerri L Cavanaugh, Alexander Chang, Susan Crowley, Cynthia Delgado, Michelle M Estrella, Cybele Ghossein, T Alp Ikizler, Holly Koncicki, Wendy St Peter, Katherine Tuttle, and Jeffrey William
Insulin Icodec., Matthew Nelson
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis., Brendon L Neuen, Robert A Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil Badve, Katherine Tuttle, Richard Pratley, Hertzel C Gerstein, Vlado Perkovic, and Hiddo J L Heerspink
Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease., Brendon L Neuen, Katherine Tuttle, and Muthiah Vaduganathan
Comparison of outcomes between single-port and multi-port robotic radical nephrectomy., Kennedy E Okhawere, Shirin Razdan, Jewel Bamby, Indu Saini, Laura Zuluaga, Ruben Calvo Sauer, Nicolas Soputro, Daniel D Eun, Akshay Bhandari, Ashok K Hemal, James R Porter, Ronney Abaza, Ahmed Mansour, Mutahar Ahmed, Simone Crivellaro, Phillip M Pierorazio, Nirmish Singla, Jihad Kaouk, Michael D Stifelman, and Ketan K Badani
Characterization of, Eric Ovruchesky, Elizabeth Pan, Melis Guer, Andrew Elliott, Shankar Siva, Praful Ravi, Bradley McGregor, Aditya Bagrodia, Ithaar Derweesh, Pedro Barata, Elisabeth I Heath, Emmanuel S Antonarakis, Sourat Darabi, Dave SB Hoon, Amir Mortazavi, Toni K Choueiri, Chadi Nabhan, Shuanzeng Wei, and Rana R McKay
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)., Pablo E Pergola, Michael Davidson, Camilla Jensen, Amir A Mohseni Zonoozi, Dominic S Raj, Philip Andreas Schytz, Katherine Tuttle, and Vlado Perkovic
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)., Pablo E Pergola, Michael Davidson, Camilla Jensen, Amir A Mohseni Zonoozi, Dominic S Raj, Philip Andreas Schytz, Katherine Tuttle, and Vlado Perkovic
Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply., Vlado Perkovic, Katherine Tuttle, and Richard Pratley
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes., Vlado Perkovic, Katherine R Tuttle, Peter Rossing, Kenneth W Mahaffey, Johannes F E Mann, George Bakris, Florian M M Baeres, Thomas Idorn, Heidrun Bosch-Traberg, Nanna Leonora Lausvig, Richard Pratley, and FLOW Trial Committees and Investigators
High-Frequency 10-kHz Spinal Cord Stimulation Provides Long-term (24-Month) Improvements in Diabetes-Related Pain and Quality of Life for Patients with Painful Diabetic Neuropathy., Erika A Petersen, Thomas G Stauss, James A Scowcroft, Michael J Jaasma, Deborah R Edgar, Judith L White, Shawn M Sills, Kasra Amirdelfan, Maged N Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis G Patterson, Michael J Creamer, Vincent Galan, Richard H Bundschu, Neel D Mehta, Dawood Sayed, Shivanand P Lad, David J DiBenedetto, Khalid A Sethi, Johnathan H Goree, Matthew T Bennett, Nathan J Harrison, Atef F Israel, Paul Chang, Paul W Wu, Charles E Argoff, Christian E Nasr, Rod S Taylor, David L Caraway, and Nagy A Mekhail
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial., Richard E Pratley, Katherine Tuttle, Peter Rossing, Søren Rasmussen, Vlado Perkovic, Olav Wendelboe Nielsen, Johannes F E Mann, Richard J MacIsaac, Mikhail N Kosiborod, Zdravko Kamenov, Thomas Idorn, Marco Bo Hansen, Samy Hadjadj, George Bakris, Florian M M Baeres, and Kenneth W Mahaffey
Nursing Dietary Intake and Continuous Blood Glucose Measurement, Teresa Rangel and Rachel Carlson
Perceptions of Providing Continuous Blood Glucose Data for a Research Study, Teresa Rangel and Rachel Carlson
Prevalence of Chronic Kidney Disease in Type 1 Diabetes Among Adults in the U.S., Peter Rossing, Per-Henrik Groop, Rakesh Singh, Robert Lawatscheck, and Katherine Tuttle
Experiences and Impacts Associated with a Spanish Language Cooking and Gardening Pilot Program, Sarah E Roth, Benjamin Gronowski, and Roma Leiva
Preanalytical considerations in quantifying circulating miRNAs that predict end-stage kidney disease in diabetes., Eiichiro Satake, Bozena Krolewski, Hiroki Kobayashi, Zaipul I Md Dom, Joseph Ricca, Jonathan M Wilson, Dave Hoon, Kevin L Duffin, Marcus G Pezzolesi, and Andrzej S Krolewski
Universal Fetal Echocardiography for Pregestational Diabetes Mellitus: A Cost-Effectiveness Analysis., Leah M Savitsky, Caitlin Hamilton, Mary Sterrett, Kelsey Olerich, Kimberly Ma, and Catherine M Albright
Association of mental health-related patient reported outcomes with blood pressure in adults and children with primary proteinuric glomerulopathies., Matthew Schuchman, Tammy M Brady, Dorey A Glenn, Katherine Tuttle, Gabriel Cara-Fuentes, Rebecca V Levy, Agustin Gonzalez-Vicente, Fadhl M Alakwaa, Tarak Srivastava, and Christine B Sethna
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial., Meghan E Sise, Jose Ramon Santos, Jason D Goldman, Katherine Tuttle, J Pedro Teixeira, Allan F Seibert, Yiannis Koullias, Joe Llewellyn, Sean Regan, Yang Zhao, Hailin Huang, Robert H Hyland, Anu Osinusi, Helen Winter, Rita Humeniuk, Henry N Hulter, Robert L Gottlieb, Dahlene N Fusco, Rita Birne, Fernando F Stancampiano, Claudia R Libertin, Catherine B Small, Markus Plate, Mark J McPhail, REDPINE Investigators, and Katherine Tuttle
ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study, SA Srour, Brendan Curti, and See full list of authors in comments
Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today., Howard Trachtman, Hailey Desmond, Amanda L Williams, Laura H Mariani, Sean Eddy, Wenjun Ju, Laura Barisoni, Heather K Ascani, Wendy R Uhlmann, Cathie Spino, Lawrence B Holzman, John R Sedor, Crystal Gadegbeku, Lalita Subramanian, Chrysta C Lienczewski, Tina Manieri, Scott J Roberts, Debbie S Gipson, Matthias Kretzler, NEPTUNE investigators, and Katherine Tuttle (NEPTUNE investigators)
Journal names its 25 People of Influence in 2025, Katherine Tuttle (author mention)
379. SGLT Inhibitors: The Biology of SGLT Inhibition with Dr. Katherine Tuttle, Katherine Tuttle
“Adjunctive Therapy in T1D”, Katherine Tuttle
“A Pinch of Salt – A Podcast by ERA”, Katherine Tuttle
“Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status of Risk in the FLOW Trial.", Katherine Tuttle
“Benefits of semaglutide on chronic kidney disease outcomes by cardiovascular status or risk in the FLOW trial.", Katherine Tuttle
“Building your academic career portfolio”, Katherine Tuttle
“Cardiovascular-Kidney-Metabolic Syndrome, Katherine Tuttle
“Cases in Diabetes, Kidney, and Cardio-Renal-Metabolic Disease”, Katherine Tuttle
CKD screening for better kidney health: Why? Who? How? When?, Katherine Tuttle
Clinical and Mechanistic Effects of GLP-1 Receptor Agonists in CKD, Katherine Tuttle
“Diabetic Nephropathy 2024: Comprehensive Care for People with Diabetes Mellitus and Advanced Chronic Kidney Disease.", Katherine Tuttle
“DM and CKD Treatments: Which Treatment Should I Use for Different Populations?”, Katherine Tuttle
“Effects of Semaglutide on CKD in Patients with Type 2 Diabetes (FLOW)”, Katherine Tuttle
“Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.”, Katherine Tuttle
“FLOW: A new treatment paradigm for people with T2D and chronic kidney disease”, Katherine Tuttle
“FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk.”, Katherine Tuttle
“FLOW Result: Summary and Clinical Implication, Katherine Tuttle
“FLOW: Semaglutide scores big in diabetic patients with CKD”, Katherine Tuttle
“ GLP1-RA in CKD”, Katherine Tuttle
GLP-1 Receptor Agonists for CKD in Diabetes and Beyond…, Katherine Tuttle
“GLP-1 Receptor Agonists for CKD in Diabetics and Beyond”, Katherine Tuttle
“Glycemic Management in Persons with Diabetes and CKD”, Katherine Tuttle
“Going with the FLOW: Understanding the renal effects of GLP-1RA Therapy”, Katherine Tuttle
Helio “Aldosterone inhibitor BI 690517 reduced albuminuria when combined with SGLT2 inhibitor”, Katherine Tuttle
Horizons-EASD eLearning, Katherine Tuttle
“How GLP1 receptor agonist evolved from weight management drug to kidney protective therapy”, Katherine Tuttle
“How Will the Incretin Data “FLOW” into Practice?”, Katherine Tuttle
“ Key considerations for tailoring treatment approaches for diabetic patients with chronic kidney disease", Katherine Tuttle
“Kidney Compass Podcast with Drs. Neuen/Wadhwani & Tuttle, Katherine Tuttle
“Kidney Disease and Obesity”, Katherine Tuttle
“Kidney Health for All: Advancing equitable access to care and optimal medication practice”, Katherine Tuttle
“Kidney Week 2024 Press Conference”, Katherine Tuttle
“Kidney Week 2024 Video Interview”, Katherine Tuttle
“Landmark studies”, Katherine Tuttle
“Miracle weight-loss drugs could halt kidney disease too”, Katherine Tuttle
"National Academies Workshop – Preparing the Future Workforce in Drug andResearch Development", Katherine Tuttle
National Geographic Interview feature article, Katherine Tuttle
“Navigating the Sea Change of CKD Treatment in Diabetes”, Katherine Tuttle
“Nephrology Times Interview”, Katherine Tuttle
“New study shows Ozempic lowers kidney disease”, Katherine Tuttle
“New use for Ozempic”, Katherine Tuttle
“Ozempic cuts risk in kidney disease”, Katherine Tuttle
“Ozempic cuts risk of chronic kidney disease complications, study finds””, Katherine Tuttle
“Ozempic keeps wowing: trial data show benefits for kidney disease”, Katherine Tuttle
“Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds", Katherine Tuttle
Plenary - “Kidney Health and CKD Prevention Herald a Sea Change in Nephrology”, Katherine Tuttle
Research Development., Katherine Tuttle
“Sea Change in CKD”, Katherine Tuttle
“Semaglutide cuts kidney failure and death in diabetes”, Katherine Tuttle
“Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial”, Katherine Tuttle
“Semaglutide significantly improves chronic kidney disease”, Katherine Tuttle
“State-of-are Treatment for DKD”, Katherine Tuttle
“State of the art treatment for CKD”, Katherine Tuttle
“Study crystallizes distinct kidney benefits of common drug”, Katherine Tuttle
“Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early.”, Katherine Tuttle
Talk with a Doc Podcast, Katherine Tuttle
The FLOW Trial of Semaglutide for CKD in Type 2 Diabetes: Kidney, Cardiovascular, and Mortality Outcomes, Katherine Tuttle
“The Next Stage: CKM Syndrome Progression and Implications for CVD Outcomes”, Katherine Tuttle
“Therapeutic Transformation of Chronic Kidney Disease”, Katherine Tuttle
“Therapeutic Transformation of Kidney Care – Diabetes and Beyond”, Katherine Tuttle
“Transformation of CKD Care to Delivery Kidney Health”, Katherine Tuttle
“Transforming CKD Care from Evidence Generation to Implementation”, Katherine Tuttle
Transforming CKD Care from Evidence Generation to Implementation, Katherine Tuttle
“Transforming Kidney Care – Breakthrough Therapies”, Katherine Tuttle
“Transforming Kidney Care by Equitable Implementation of Breakthrough Therapies”, Katherine Tuttle
Treatment of Chronic Kidney Disease and Heart Failure Circa 2024, Katherine Tuttle
“Why diabetes miracle drugs like Ozempic are off-limits to Type 1s”, Katherine Tuttle
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis., Katherine Tuttle, Clint W Abner, Patrick D Walker, Kaijun Wang, Andrew Rava, Jihaeng Heo, and Martin Bunke
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis., Katherine Tuttle, Clint W Abner, Patrick D Walker, Kaijun Wang, Andrew Rava, Jihaeng Heo, and Martin Bunke
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial., Katherine Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J L Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw, and Peter Rossing
Combination therapy for kidney disease in people with diabetes mellitus., Daniël H van Raalte, Petter Bjornstad, David Z I Cherney, Ian H de Boer, Paola Fioretto, Daniel Gordin, Frederik Persson, Sylvia E Rosas, Peter Rossing, Jennifer A Schaub, Katherine Tuttle, Sushrut S Waikar, and Hiddo J L Heerspink
Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study., Chia-Shi Wang, Dorey A Glenn, Margaret Helmuth, Abigail R Smith, Andrew S Bomback, Pietro A Canetta, Gaia M Coppock, Myda Khalid, Katherine Tuttle, Raed Bou-Matar, Larry A Greenbaum, Bruce M Robinson, Lawrence B Holzman, William E Smoyer, Michelle N Rheault, Debbie Gipson, Laura H Mariani, and Cure Glomerulonephropathy (CureGN) Study Consortium
